{"disease":{"id":"cryoglobulinemic-vasculitis","name":"cryoglobulinemic vasculitis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03410290","title":"Journey of Patients With Vasculitis From First Symptom to Diagnosis","phase":"","overall_status":"COMPLETED","enrollment_count":456,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT04692363","title":"Plasmapheresis Before Rituximab in Cryoglobulinemia","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT07268521","title":"A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05168475","title":"Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"Cambridge University Hospitals NHS Foundation Trust","has_results":true},{"nct_id":"NCT05114109","title":"Isatuximab in Type I Cryoglobulinemia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":21,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}